Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer

E-ISSN： 1875-5992|9|10|1058-1069

ISSN： 1871-5206

Source： Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol.9, Iss.10, 2009-12, pp. : 1058-1069

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives

By Lassi Kiran Dawson Nancy A

Future Oncology, Vol. 7, Iss. 4, 2011-04 ,pp. : 551-558

Future Medicine

Access to resources Recommend Favorite

Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 3, 2011-03 ,pp. : 296-306

Bentham Science Publishers

Access to resources Recommend Favorite

Recent advances revolutionize treatment of metastatic prostate cancer

By Madan Ravi A Arlen Philip M

Future Oncology, Vol. 9, Iss. 8, 2013-08 ,pp. : 1133-1144

Future Medicine

Access to resources Recommend Favorite

Current perspectives in the treatment of advanced prostate cancer

By Valdespino Victor Tsagozis Panagiotis Pisa Pavel

Medical Oncology, Vol. 24, Iss. 3, 2007-09 ,pp. : 273-286

Humana Press, Inc

Access to resources Recommend Favorite

The Assessment of Treatment Outcomes in Metastatic Prostate Cancer: Changing Endpoints

By Dawson N.A. McLeod D.G.

European Journal of Cancer, Vol. 33, Iss. 4, 1997-04 ,pp. : 560-565

Elsevier

Access to resources Recommend Favorite